arrow
J

Jessica Beltrán

Pontificia Universidad Catolica de Chile
H指数:19
被引数:1,624

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Artificial Intelligence-enabled GRADE: how the GRADE Working Group will use automation to rate the certainty of evidence of intervention effects

人工智能赋能的GRADE:GRADE工作组将如何利用自动化对干预效应的证据确定性进行评级

2026-08-010
PRE
Protocol: Scoping review of the association between complementary feeding, growth, and immune health in infants and toddlers—An EAACI guideline paper

方案:婴幼儿补充喂养、生长和免疫健康的关联范围综述——EAACI指南文件

2025-08-010
PRE
The Rhodoexplorer Platform for Red Algal Genomics and Whole-Genome Assemblies for Several Gracilaria Species
2023-07-225
OAAI
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

dupilumab治疗中度至重度特应性皮炎的疗效和安全性: EAACI生物制剂指南的系统评价

2020-10-0440
OAAI
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

奥马珠单抗治疗慢性自发性荨麻疹的疗效和安全性: EAACI生物制剂指南的系统评价

2020-09-0754
OAAI
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

生物制剂 (benralizumab,dupilumab和omalizumab) 治疗严重过敏性哮喘的有效性和安全性: EAACI指南的系统评价-关于在严重哮喘中使用生物制剂的建议

2020-05-1891
OAAI
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

dupilumab治疗重度哮喘的有效性和安全性: EAACI指南的系统评价-关于在重度哮喘中使用生物制剂的建议

2020-04-0164
OAAI
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

生物制剂 (benralizumab,dupilumab,mepolizumab,omalizumab和reslizumab) 治疗严重嗜酸性粒细胞性哮喘的疗效和安全性

2020-02-24258
OAAI